PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Alimera Sciences, Inc. (ALIM)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS0162592028
CUSIP016259202
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic

Highlights

Market Cap$174.86M
EPS-$0.84
Revenue (TTM)$80.75M
Gross Profit (TTM)$52.00M
EBITDA (TTM)$6.82M
Year Range$1.56 - $4.38
Target Price$8.00
Short %0.22%
Short Ratio1.24

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Alimera Sciences, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Alimera Sciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%10.00%20.00%30.00%40.00%NovemberDecember2024FebruaryMarchApril
15.79%
21.14%
ALIM (Alimera Sciences, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Alimera Sciences, Inc. had a return of -15.97% year-to-date (YTD) and 72.45% in the last 12 months. Over the past 10 years, Alimera Sciences, Inc. had an annualized return of -27.43%, while the S&P 500 had an annualized return of 10.55%, indicating that Alimera Sciences, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-15.97%6.33%
1 month-9.02%-2.81%
6 months15.97%21.13%
1 year72.45%24.56%
5 years (annualized)-24.51%11.55%
10 years (annualized)-27.43%10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-15.51%-3.01%10.17%
2023-5.78%8.06%-7.91%40.03%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of ALIM is 80, placing it in the top 20% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of ALIM is 8080
Alimera Sciences, Inc.(ALIM)
The Sharpe Ratio Rank of ALIM is 8181Sharpe Ratio Rank
The Sortino Ratio Rank of ALIM is 8181Sortino Ratio Rank
The Omega Ratio Rank of ALIM is 7777Omega Ratio Rank
The Calmar Ratio Rank of ALIM is 7878Calmar Ratio Rank
The Martin Ratio Rank of ALIM is 8585Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alimera Sciences, Inc. (ALIM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ALIM
Sharpe ratio
The chart of Sharpe ratio for ALIM, currently valued at 1.10, compared to the broader market-2.00-1.000.001.002.003.001.10
Sortino ratio
The chart of Sortino ratio for ALIM, currently valued at 1.96, compared to the broader market-4.00-2.000.002.004.006.001.96
Omega ratio
The chart of Omega ratio for ALIM, currently valued at 1.22, compared to the broader market0.501.001.501.22
Calmar ratio
The chart of Calmar ratio for ALIM, currently valued at 0.76, compared to the broader market0.001.002.003.004.005.006.000.76
Martin ratio
The chart of Martin ratio for ALIM, currently valued at 5.95, compared to the broader market0.0010.0020.0030.005.95
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.91, compared to the broader market-2.00-1.000.001.002.003.001.91
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.77, compared to the broader market-4.00-2.000.002.004.006.002.77
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.46, compared to the broader market0.001.002.003.004.005.006.001.46
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.61, compared to the broader market0.0010.0020.0030.007.61

Sharpe Ratio

The current Alimera Sciences, Inc. Sharpe ratio is 1.10. A Sharpe ratio greater than 1.0 is considered acceptable.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00NovemberDecember2024FebruaryMarchApril
1.10
1.91
ALIM (Alimera Sciences, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Alimera Sciences, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-98.01%
-3.48%
ALIM (Alimera Sciences, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alimera Sciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alimera Sciences, Inc. was 99.26%, occurring on Mar 22, 2023. The portfolio has not yet recovered.

The current Alimera Sciences, Inc. drawdown is 98.01%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.26%Nov 26, 20103100Mar 22, 2023
-40.14%Apr 29, 201054Jul 15, 201077Nov 2, 2010131
-10.42%Nov 3, 20104Nov 8, 201010Nov 22, 201014
-0.32%Apr 27, 20101Apr 27, 20101Apr 28, 20102

Volatility

Volatility Chart

The current Alimera Sciences, Inc. volatility is 13.27%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%NovemberDecember2024FebruaryMarchApril
13.27%
3.59%
ALIM (Alimera Sciences, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alimera Sciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items